Fluticasone propionate; salmeterol xinafoate
Fluticasone propionate; salmeterol xinafoate: 3 brands, 5 generics; first approved Aug 24, 2000; generic available.
Generic available: 5 ANDA applications approved.
Brand (NDA) products
- TEVA PHARMNDA 20879920196 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.055MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Rx - 0.113MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Rx - 0.232MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Rx - 0.055MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Discontinued - 0.113MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Discontinued - 0.232MG/INH;EQ 0.014MG BASE/INH POWDER INHALATION Discontinued - - GLAXO GRP LTDNDA 02125420063 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.045MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED INHALATION Rx - 0.115MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED INHALATION Rx - 0.23MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED INHALATION Rx - - GLAXO GRP LTDNDA 02107720003 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.5MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB
Generic (ANDA) products (5)
- CIPLAANDA 21308720263 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.5MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB - RESPIRENT PHARMSANDA 21446420262 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB - TEVA PHARMS USAANDA 21394820213 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.5MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB - HIKMAANDA 20343320203 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.5MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB - MYLANANDA 20889120193 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.25MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB 0.5MG/INH;EQ 0.05MG BASE/INH POWDER INHALATION Rx AB
Patent & exclusivity timeline
Listed patents
| Patent | Expires | In | Type |
|---|---|---|---|
| 10195375 | in 4 yr 4 mo | Product | |
| 10195375*PED | in 4 yr 10 mo | ||
| 9415008 | in 8 yr | ProductU-645 | |
| 9066957 | in 8 yr | ProductU-645 | |
| 9415008*PED | in 8 yr 6 mo | ||
| 9066957*PED | in 8 yr 6 mo | ||
| 10918816 | in 9 yr 2 mo | Product | |
| 10918816*PED | in 9 yr 8 mo | ||
| 11969544 | in 12 yr 11 mo | Product | |
| 11344685 | in 13 yr | Product | |
| 11969544*PED | in 13 yr 5 mo | ||
| 11344685*PED | in 13 yr 6 mo | ||
| 11173259 | in 13 yr 10 mo | Product | |
| 11173259*PED | in 14 yr 4 mo |
Approval history
Approvals span 2000โ2026 across 8 FDA applications.
Fluticasone propionate; salmeterol xinafoate: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Fluticasone propionate; salmeterol xinafoate
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo
